Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2001-7-12
pubmed:abstractText
Cardiac hypertrophy is one of the serious complications which increase mortality due to cardiovascular diseases. However, only a partial reduction of cardiac hypertrophy has been successful using current drug therapy. We demonstrate here reduction of cardiac hypertrophy in vitro and in vivo using an adenovirus vector encoding cyclin-dependent kinase (cdk) inhibitor p16INK4a. Adenovirus-mediated overexpression of cdk inhibitor p16INK4a completely inhibited cardiac myocyte hypertrophy induced by endothelin (ET)-1, as evaluated by [3H]leucine incorporation into the cells and mRNA levels of skeletal alpha -actin (SK-A) or atrial natriuretic peptide (ANP) as well as by morphometric analyses. We then evaluated whether p16INK4a can suppress left-ventricular (LV) hypertrophy induced by aortic banding (AOB) in rats. Catheter-mediated gene transfer of AxCAp16 was performed according to the method reported by Hajjar et al. LV overload was produced by coarctation of the ascending aorta immediately after inoculation of the heart with adenovirus. Two weeks after the procedure, the left ventricular weight/body weight ratio (LVW/BW) increased in the AOB+LacZ group in comparison to that in controls. However, LVW/BW was identical in the AOB+p16 group and controls. Histologic analysis revealed that p16INK4a inhibited hypertrophy of cardiac myocytes. These results suggest that G1 cell cycle regulators may restrict cardiac hypertrophy, and offer a novel strategy for the gene therapy of cardiac hypertrophy.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0022-2828
pubmed:author
pubmed:copyrightInfo
Copyright 2001 Academic Press.
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1493-504
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11448137-Actins, pubmed-meshheading:11448137-Adenoviridae, pubmed-meshheading:11448137-Animals, pubmed-meshheading:11448137-Animals, Newborn, pubmed-meshheading:11448137-Atrial Natriuretic Factor, pubmed-meshheading:11448137-Cardiomegaly, pubmed-meshheading:11448137-Cells, Cultured, pubmed-meshheading:11448137-Cyclin-Dependent Kinases, pubmed-meshheading:11448137-Endothelin-1, pubmed-meshheading:11448137-Gene Expression, pubmed-meshheading:11448137-Gene Therapy, pubmed-meshheading:11448137-Gene Transfer Techniques, pubmed-meshheading:11448137-Genes, p16, pubmed-meshheading:11448137-Genetic Vectors, pubmed-meshheading:11448137-Myocardium, pubmed-meshheading:11448137-RNA, Messenger, pubmed-meshheading:11448137-Rats, pubmed-meshheading:11448137-Rats, Inbred Strains, pubmed-meshheading:11448137-Receptors, Endothelin, pubmed-meshheading:11448137-Transfection
pubmed:year
2001
pubmed:articleTitle
Overexpression of cdk Inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy.
pubmed:affiliation
Second Department of Internal Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't